336 related articles for article (PubMed ID: 23699676)
1. How does use of a prescription monitoring program change pharmacy practice?
Green TC; Mann MR; Bowman SE; Zaller N; Soto X; Gadea J; Cordy C; Kelly P; Friedmann PD
J Am Pharm Assoc (2003); 2013; 53(3):273-81. PubMed ID: 23699676
[TBL] [Abstract][Full Text] [Related]
2. How does use of a prescription monitoring program change medical practice?
Green TC; Mann MR; Bowman SE; Zaller N; Soto X; Gadea J; Cordy C; Kelly P; Friedmann PD
Pain Med; 2012 Oct; 13(10):1314-23. PubMed ID: 22845339
[TBL] [Abstract][Full Text] [Related]
3. Pharmacists Who Screen and Discuss Opioid Misuse With Patients: Future Directions for Research and Practice.
Cochran G; Field C; Lawson K
J Pharm Pract; 2015 Aug; 28(4):404-12. PubMed ID: 24532819
[TBL] [Abstract][Full Text] [Related]
4. Prescribers and pharmacists requests for prescription monitoring program (PMP) data: does PMP structure matter?
Fleming ML; Chandwani H; Barner JC; Weber SN; Okoro TT
J Pain Palliat Care Pharmacother; 2013 Jun; 27(2):136-42. PubMed ID: 23688495
[TBL] [Abstract][Full Text] [Related]
5. Pharmacists' training, perceived roles, and actions associated with dispensing controlled substance prescriptions.
Fleming ML; Barner JC; Brown CM; Shepherd MD; Strassels SA; Novak S
J Am Pharm Assoc (2003); 2014; 54(3):241-50. PubMed ID: 24816350
[TBL] [Abstract][Full Text] [Related]
6. Integration of prescription drug monitoring programs (PDMP) in pharmacy practice: Improving clinical decision-making and supporting a pharmacist's professional judgment.
Norwood CW; Wright ER
Res Social Adm Pharm; 2016; 12(2):257-66. PubMed ID: 26143489
[TBL] [Abstract][Full Text] [Related]
7. Pharmacy-based statewide naloxone distribution: A novel "top-down, bottom-up" approach.
Morton KJ; Harrand B; Floyd CC; Schaefer C; Acosta J; Logan BC; Clark K
J Am Pharm Assoc (2003); 2017; 57(2S):S99-S106.e5. PubMed ID: 28292508
[TBL] [Abstract][Full Text] [Related]
8. Factors influencing community pharmacists' enrollment in a state prescription monitoring program.
Ulbrich TR; Dula CA; Green CG; Porter K; Bennett MS
J Am Pharm Assoc (2003); 2010; 50(5):588-94. PubMed ID: 20833616
[TBL] [Abstract][Full Text] [Related]
9. Indian Health Service pharmacists engaged in opioid safety initiatives and expanding access to naloxone.
Duvivier H; Gustafson S; Greutman M; Jangchup T; Harden AK; Reinhard A; Warshany K
J Am Pharm Assoc (2003); 2017; 57(2S):S135-S140. PubMed ID: 28292501
[TBL] [Abstract][Full Text] [Related]
10. Do prescription monitoring programs impact state trends in opioid abuse/misuse?
Reifler LM; Droz D; Bailey JE; Schnoll SH; Fant R; Dart RC; Bucher Bartelson B
Pain Med; 2012 Mar; 13(3):434-42. PubMed ID: 22299725
[TBL] [Abstract][Full Text] [Related]
11. Development and delivery of a pharmacist training program to increase naloxone access in Kentucky.
Palmer E; Hart S; Freeman PR
J Am Pharm Assoc (2003); 2017; 57(2S):S118-S122. PubMed ID: 28161300
[TBL] [Abstract][Full Text] [Related]
12. Exploratory study of emergency physicians' use of a prescription monitoring program using a framework of technology acceptance.
Fleming ML; Hatfield MD; Wattana MK; Todd KH
J Pain Palliat Care Pharmacother; 2014 Mar; 28(1):19-27. PubMed ID: 24520884
[TBL] [Abstract][Full Text] [Related]
13. An opioid dispensing and misuse prevention algorithm for community pharmacy practice.
Rickles NM; Huang AL; Gunther MB; Chan WJ
Res Social Adm Pharm; 2019 Aug; 15(8):959-965. PubMed ID: 29525483
[TBL] [Abstract][Full Text] [Related]
14. Analysis of community chain pharmacists' interventions on electronic prescriptions.
Warholak TL; Rupp MT
J Am Pharm Assoc (2003); 2009; 49(1):59-64. PubMed ID: 19196598
[TBL] [Abstract][Full Text] [Related]
15. Clinical decision making involving prescription drug monitoring programs: A factorial, vignette-based study among student pharmacists.
Tata V; Varisco TJ; Du N; Nguyen J; Haghparast P; Thornton JD
J Am Pharm Assoc (2003); 2021; 61(3):316-324. PubMed ID: 33579594
[TBL] [Abstract][Full Text] [Related]
16. Use and Misuse of Opioids in Maine: Results From Pharmacists, the Prescription Monitoring, and the Diversion Alert Programs.
Piper BJ; Desrosiers CE; Lipovsky JW; Rodney MA; Baker RP; McCall KL; Nichols SD; Martin SL
J Stud Alcohol Drugs; 2016 Jul; 77(4):556-65. PubMed ID: 27340958
[TBL] [Abstract][Full Text] [Related]
17. Pharmacists' role in opioid overdose: Kentucky pharmacists' willingness to participate in naloxone dispensing.
Freeman PR; Goodin A; Troske S; Strahl A; Fallin A; Green TC
J Am Pharm Assoc (2003); 2017; 57(2S):S28-S33. PubMed ID: 28139459
[TBL] [Abstract][Full Text] [Related]
18. Assessment of Prescriber and Pharmacy Shopping Among the Family Members of Patients Prescribed Opioids.
Chua KP; Brummett CM; Conti RM; Haffajee RL; Prosser LA; Bohnert ASB
JAMA Netw Open; 2019 May; 2(5):e193673. PubMed ID: 31074819
[TBL] [Abstract][Full Text] [Related]
19. Pharmacist utilization of prescription opioid misuse interventions: Acceptability among pharmacists and patients.
Riley TB; Alemagno S
Res Social Adm Pharm; 2019 Aug; 15(8):986-991. PubMed ID: 30665825
[TBL] [Abstract][Full Text] [Related]
20. Class-wide REMS for extended-release and long-acting opioids: potential impact on pharmacies.
Matthews ML
J Am Pharm Assoc (2003); 2013; 53(1):e1-7. PubMed ID: 23636166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
